

Supplementary Material

Table 1 Supplementary. Patients' basal features according to specific drugs.

	Bamlanivimab-Etesevimab	Molnupinavir	Nimatrelvir - Ritonavir	Remdesivir	Sotrovimab
Patient n. (%)	1/32 (3)	2/32 (6.2)	3/32 (9.3)	7/32 (21.8)	19/32 (59.7)
Gender					
<i>F</i> n. (%)	1 (100)	1 (50)	1 (33)	2 (28.5)	10 (52.6)
<i>M</i> n. (%)	0	1 (50)	2 (67)	5 (71.5)	9 (47.4)
Age (years)^{1,2}	6	9.7-10.3 ¹	15-18 ¹	2.5 (4.25,6.75) ²	8.44 (4.88,10.83) ²
Age, categorical (years)^{1,2}					
<=2	0	0	0	1	3
>2	1	2	3	6	16
Weight (kg)	24.2	42.5-45 ¹	59-65 ¹	15.5 (6.5,22) ²	23.5 (6.5,30) ²
Baseline disease n. (%)					
<i>Oncohematological</i>	1 (100)	2 (100)	2 (66.6)	6 (85.7)	11 (57.8)
<i>Solid Organ Transplantation</i>	0	0	0	0	4 (21.1)
<i>Other</i>	0	0	1 (33.4)	1 (14.3)	4 (21.1)
COVID-19 vaccination n. (%)					
<i>No</i>	1 (100)	2 (100)	3 (100)	7 (100)	19 (100)
Steroid therapy	1(100)	2 (100)	0	2 (25.8)	8 (42)
Polytherapy	1(100)	2 (100)	3 (100)	2 (25.8)	11 (57.8)
COVID-19 symptoms n. (%)					
<i>Asymptomatic</i>	1 (100)	1 (50)	2 (66.6)	3 (42.8)	4 (21)
<i>Mild symptoms</i>	0	1 (50)	1 (33.4)	4 (57.2)	15 (79)
Mechanical ventilation n. (%)	0	0	0	0	0
Non-invasive ventilation n. (%)	1 (100)	0	0	0	0
Oxygen requirement n. (%)	1 (100)	0	0	1 (14.2)	1 (5.2)
Off-label prescription n. (%)	1 (100)	2 (100)	2 (66.6)	7 (100)	15 (78.9)
Serum creatinine (μmol/L)	15	23-118 ¹	35-60 ¹	18 (30,31) ²	40.5 (29,56.7) ²
AST (U/L)	69	13-24 ¹	28-71 ¹	67 (47,89) ²	42 (27.5,66) ²
ALT (U/L)	39	6-35 ¹	39-125 ¹	70 (33.5,87) ²	44 (24,75.7) ²
Symptoms after 7 days n. (%)					
<i>Asymptomatic</i>	1 (100)	2 (100)	1 (33.4)	5 (71.4)	17 (89.4)
<i>Still Symptoms</i>	0	0	1 (33.4)	1 (14.2)	1 (5.2)
Positivity after 7 days n. (%)					

<i>Negative</i>	0	0	/	/	1 (5.2)
<i>Positive</i>	1 (100)	2 (100)	2 (66.6)	6 (85.7)	15 (78.9)
Symptoms after 28 days n. (%)					
<i>Asymptomatic</i>	0	2 (100)	2 (66.6)	6 (85.7)	16 (84.2)
<i>Still symptoms</i>	1 (100)	0	/	/	/
Positivity after 28 days n. (%)					
<i>Negative</i>	0	1 (50)	1 (33.4)	4 (57.1)	11 (57.8)
<i>Positive</i>	1 (100)	1 (50)	1 (33.4)	2 (28.5)	4 (21)
Severe ADR n. (%)					
<i>No</i>	1 (100)	2 (100)	3 (100)	7 (100)	19 (100)
Death for other causes n. (%)	0	0	0	1 (14.2)	2 (10.5)
Lost at follow-up at 7 days	0	0	1 (33.)	0	0
Lost at follow-up at 28 days	0	0	0	0	1 (5.2)
1 Range, 2 Median (Interquartile range)					